PATENT CLAIM ANALYSIS

Application Number: 15927327
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "093700"]

Abstract:
The invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. The invention is specifically directed to treating disorders, diseases and injuries of the cornea and ocular surface, treating retinal disorders, diseases and injuries and optic nerve disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents.

Claim (Index 21):
The method of  claim 20  wherein the active agents are VEGF inhibitors selected from the group consisting Eylea\u00ae (aflibercept) VEGF inhibitor, Macugen\u00ae (pegaptanib sodium injection) VEGF inhibitor, Avastin\u00ae (bevacizumab injection) VEGF inhibitor, and Lucentis\u00ae (ranibizumab injection) VEGF inhibitor.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 2.94118
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14556300', '14276140', '13374166', '15492446', '14525654']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7140601417241197
- 35 USC 102 Novelty (BERT): 0.5272935001757647
- Combined Prediction Score: 0.6953834775692842
- Mean Citation Score: 188.23888
- Max Citation Score: 256.34558
- Similarity Product: 130.61148715851903

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test